IPR challenge information from the Article: What Are

New Post Public Reply Private Reply Replies (0) Message Board
CyberC
488
IPR challenge information from the Article:

What Are the Legal Challenges With Intellectual Property?
Thursday, January 28, 2016 - by Steve Cohen

The legal challenges related to intellectual property is often a very slippery slope. Steve Cohen reviews so elementary views about the laws so you can protect your work and your organization.
Let me begin this blog with two very important disclaimers. First, I am not an attorney, so the information I am presenting has been gathered from a number of sources that are far more qualified to address the topic of intellectual property (IP). Instead, my role is to bring to the surface many of the challenges and issues you may face as a senior leader in talent development. I implore you to get real legal counsel for any particular issues you think may violate IP laws.
Second, although I am writing this post under the “so-called auspices” of ATD (because they are posting it on their community blog), anything that is reported herein (now I do sound like a lawyer J), does not necessarily represent the views or perspectives of ATD. That said, I would be surprised if there is any major disagreement about the myriad IP-related issues facing those of us working in this field.
Lastly, someone will likely challenge my use of sources. To avoid any potential IP issues, and to represent my research as accurately as possible, I am adding a reference list for readers to review on their own. Have I violated any IP laws in taking this approach? Probably, but certainly not intentionally. You will have to judge for yourself after reading this post. But while the absence of intentionality is not a suitable defense (as we will discuss below), I hope to cover my bases enough so that I am not found guilty of the very thing that I am warning you to avoid.
The legal challenges related to intellectual property is often a very slippery slope, indeed.
What Makes IP Issues Complex?
While there are definite guidelines to follow, the interpretation of them is relatively subjective. In point of fact, attorneys often disagree amongst themselves, and leave it up to the courts to settle any sort of resolution.
Furthermore, there are many misconceptions. Here’s what I can tell you for certain:
IP law is serious business. Any blatant infringement will result in serious consequences—largely financial or to the offender’s reputation.

IP laws fall under the jurisdiction of federal law. Article I, Section 8 of the U.S. Constitution grants Congress the power to promote innovation by ensuring creators are granted intellectual property rights through both the U.S. Copyright Office and the U.S. Patent and Trademark Office. It behooves practitioners dependent on third-party L&D materials and content to acquaint themselves with basic guidelines and act conservatively when making decisions about the creation and use of IP.
Cat Russo, of Russo Rights, helps manages intellectual property issues for ATD. She explains the issue in simple terms: “If you didn’t write something as your own original content and if it’s not your original idea but you are using that material in any kind of published work that someone else will be reading (for internal or external organizational use), it’s best to always request permission from the copyright holder. In addition, be sure to include an attribution ‘Used with permissions from the COPYRIGHT HOLDER NAME.’”
Some Basics of Intellectual Property Law
Let’s begin with some elementary facts about the laws—so we are all starting from the same place. (And yes, intellectual property law is, in fact, a large enough issue to have its own category and specialists who do nothing but litigate in this arena.)
In general terms, it refers to the kind of property that results from the fruits of mental labor, and includes four primary areas: copyrights, trademarks, patents, and trade secrets. It also includes industrial design and geographical indications or appellations. Here’s a simple breakdown:


Advertisement
Patents protect inventions of tangible things.
Copyrights protect various forms of written and artistic expression.
Trademarks protect a name or symbol identifying the source of goods or services.
Trade secrets protect secret processes, distribution methods, and other confidential information.
Industrial design constitutes the ornamental or aesthetic aspect of an article.
Geographical indications represent the specific geographical origin and possess qualities essentially attributable to that place of origin such as the name of the place of origin of goods.
While any of these could apply to the development and use of learning materials, my guess is that the copyright infringement is the issue confronted most often by talent development leaders. The issues, of course, are quite different if it relates to use of your own or your organization’s original materials versus those offered by an external supplier.
The IP law cited most often in these situations is the “fair use” doctrine. The “fair use” rule, at least in the United States, permits limited use of copyrighted material without permission from the rights holders, based on the belief that the public is entitled to freely use portions of copyrighted materials for purposes of commentary and criticism. This begs the question: What exactly is and isn’t “fair use”?
Although there are limitations, the following types of uses are usually deemed fair use: criticism and comment, news reporting, research and scholarship, nonprofit educational use, and parody. There are four basic factors to test the “fair use” doctrine.
Purpose and character of the use. This refers to whether the use in question helps fulfill the intention of copyright law to stimulate creativity for the enrichment of the general public, or whether it aims to only supersede the objects of the original for reasons of personal profit.

Nature of the copyrighted work. This refers to preventing ownership of work that rightfully belongs in the public domain by separating facts and ideas from copyright, and rather that only their particular expression of fixation merits such protection.

Amount and substance. This refers to the assessment of the quantity (or percentage) of the original copyrighted work that has been imported into the new work. In this case, often a “de minimis” defense is offered on the basis that the amount of material copied is so small that a fair use analysis isn’t even conducted.

Effect upon one’s value. This refers to measuring the effect that the allegedly infringing use has had on the copyright owner’s ability to exploit the original work.
There are five basic rules to keep in mind when deciding whether or not a particular use of an author’s work is fair use:
Copying something is different from creating something. That is, are you merely copying someone else’s work verbatim, or are using it to help create something new?

You can’t compete with the source you are copying. Without permission, you usually can’t use another person’s protected expression in any way that limits or potentially impairs the market for his or her work.

Giving the author credit doesn’t let you off the hook. Giving credit and fair use are completely separate concepts. You either have the right to use someone else’s materials or you don’t. The fact that you attribute the materials doesn’t change this.

The more you take the less “fair use” it is likely to be. This seems obvious, but what exactly does “more” mean and how is it measured? As a general rule, never quote more than a few successive paragraphs from a book or article, take more than one chart or diagram, or include an illustration or other artwork in a book or newsletter without the author’s permission. Contrary to what many believe, however, there is NO absolute word limit on fair use. For example, copying 200 words from a work of 300 words would not be fair use, but copying 2,000 words from a work of 50,000 words might be.

The quality of the material used is as important as the quantity. The more important the material is to the original work, the less likely your use of it will be considered fair.
The practicality of the fair use doctrine is that a number of conventional uses of copyrighted works are not necessarily considered infringements. For instance, quoting from a copyrighted work in order to criticize or comment on it or teach students about it is considered fair use. An instructor who prints a few copies of an article to illustrate an approach or methodology will probably have no problem against the four factors—other than possibly amount and substance. All cases are not that clear, though. In most situations, all four factors are considered together in a balanced way to decide on whether the standards of fair use were violated.
Consider a program that quotes another source as an example of a point. This will probably fall under fair use, even though the program may be sold to others. However, a nonprofit educational website that reproduces whole articles from magazines will probably be found to infringe if the magazine publisher can demonstrate that the website affects the market for the magazine, even though the website is non-commercial.
Here’s the really tricky part: Just when you think this is all making sense and there are relatively easy guidelines to follow, keep in mind that countries other than the United States often have drastically different fair use criteria. In fact, in some countries, there is little or no fair use defense available. Even within Europe, rules vary greatly across countries.
Bottom line: When in doubt, always ask for permission. What’s more, even when not in doubt, ask for permission. It is the safest approach and typically results in getting that permission.

Zerify Inc (ZRFY) Stock Research Links

ZRFY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Globant Unleashes MuleSoft AI Pod for Faster Integration

Updated Category News Views 1

Unlocking the AI Puzzle: Webinar Speed Dials You ever swim through a mash-up of tech lingo that makes you feel like you're trudging through waist-high molasses? Well, Saddle up because that's exactly where Globant's new MuleSoft AI Pod is heading. Through Glob.AI, they're going all in on turning what used to take months into mere weeks—finally, right? In the business of...

Continue Reading
Syra Health Joins CMS ACCESS Model for Scalable Growth

Updated Category News Views 4

Syra Health Secures Spot in CMS ACCESS Model Every once in a while, a company gets a nod that could redefine its trajectory, and today it’s Syra Health’s turn at bat. Teaming up with HealthSync, they’ve clinched a position in the coveted CMS ACCESS model—a move not just about snagging headlines but potentially securing a golden ticket to a robust revenue stream...

Continue Reading
Médunik Canada Boosts Dravet Syndrome Support with Biocodex

Updated Category News Views 2

Breaking Down the Exclusive Médunik-Biocodex Partnership Listen, when a company like Médunik Canada, firmly rooted in Blainville, QC, throws its weight behind a rare disease drug like Diacomit®, folks in the industry take notice. Their recent handshake with Biocodex isn't just small talk; it opens doors to change how Dravet syndrome is managed across Canada. This new...

Continue Reading
Ohio's Visionary Leadership Honored with Prestigious Award

Updated Category News Views 4

Award for Exceptional Vision Care Leadership Ain't every day you see a politician scooping up awards for making a real difference in folks' lives. Yet here we are, tipping our hats to Ohio's Governor Mike DeWine, who's just been dubbed the honcho with the golden eye for children's vision care in the 12th annual Bonnie Strickland Champion for Children's Vision Award. Hats...

Continue Reading
Hamamatsu & AIxMed to Automate Cytology Workflows

Updated Category News Views 2

Why This Collaboration Matters Here comes an interesting tidbit from the world of cytology: Hamamatsu and AIxMed are banding together to tackle workflow inefficiencies. Picture this—two powerhouses coming together to create a tool that might just relieve lab technicians from the tedious task of manually checking cytology slides. In a world where efficiency is king, this...

Continue Reading
Doug Larson Takes Helm at Integra Pool Covers

Updated Category News Views 2

A Seasoned Pro Joins Integra Pool Covers Change is afoot over at Explore Industries. They just tapped Doug Larson to be the General Manager for their Integra Pool Covers division. Now, I've seen plenty of hiring announcements in my day, but this has got an interesting ring to it. With Doug on this ship, it's like bringing a wolf back to the wild. Larson's no stranger to...

Continue Reading
Nonprofit Option Rises for Specialty Physicians

Updated Category News Views 2

Reimaging Choices for Specialty Physicians In the whirlwind of healthcare, specialty physicians often find themselves between a rock and a hard place. The traditional paths are either hug a major health system or auction off to private equity, each option chaining them to systems more interested in the balance sheet than in patient care. But now, a third door opens. One...

Continue Reading
APX Bridges Crypto & Traditional Finance With New Credit Line

Updated Category News Views 0

The Future of Financial Bridging Now here's a scenario that might perk your ears up if you've ever toyed with digital assets: APX Lending is stepping up its game, bringing a regulated five-year revolving line of credit backed by Bitcoin and Ethereum to the world stage. It's like blending your grandma's tried-and-true savings approach with the whiz-bang allure of crypto. A...

Continue Reading
Jim Morey Joins Pickleman's to Drive Expansion

Updated Category News Views 3

Jim Morey: Catalyst for Pickleman's Ambitious Dreams You ever heard of a sandwich joint ready to take on the big leagues? Because that's just what Pickleman's Gourmet Café is banking on with their latest move—tapping none other than Jim Morey for their executive advisory board. And let me tell ya, this ain't some run-of-the-mill hire. We're talking about a guy who's...

Continue Reading
Photronics Investors Must Act by Sept. 4, 2026 Deadline

Updated Category News Views 1

Action Time for Photronics Investors There's nothing like a looming deadline to get the adrenaline pumping, especially when you're staring down the barrel of a federal securities class action. Photronics, Inc. (NASDAQ: PLAB) has found itself tangled in legal webs, with the clock ticking down to September 4, 2026. That’s the deadline for investors to move on being the...

Continue Reading

Top 5 Most Recently Viewed Articles

Protecting Young Athletes: Superspecs Enhances Eye Safety

Updated Category News Views 157

Empowering Youth Athletes with Eye Safety Initiatives Superspecs leads the charge in providing essential protective eyewear to ensure the safety of student-athletes as sports and recreation-related eye injuries remain a significant concern. As the only statewide initiative dedicated to safeguarding the vision of children up to the age of 18, Superspecs is actively...

Continue Reading
Tilray's Strategic Moves in the Cannabis Space: An In-Depth Look

Updated Category News Views 110

Understanding Tilray's Position in the Cannabis Market Tilray Brands (NASDAQ: TLRY) has emerged as a significant player in the cannabis sector, attracting attention from investors and analysts alike. Despite presenting a solid balance sheet and an array of international assets, its current investment standing remains cautious. Analysts have issued a 'Neutral' rating,...

Continue Reading
Citrine Power LLC Breaks Ground on Solar Project in New York

Updated Category News Views 206

Construction Begins on Solar Array by Citrine Power LLC Exciting news is on the horizon as Citrine Power LLC has officially kicked off the construction of a 3.6-MWac ground-mounted solar array. This marks a significant step forward in the pursuit of renewable energy solutions, contributing to a more sustainable future. Partnerships Fueling Development The Constable Solar...

Continue Reading
Predictive Oncology Partners with Renovaro for Improved Cancer Solutions

Updated Category News Views 171

Predictive Oncology and Renovaro's Strategic Partnership Predictive Oncology Inc. (NASDAQ: POAI), a prominent name in the field of artificial intelligence-driven drug discovery, is embarking on an exciting new chapter with its strategic partner Renovaro Biosciences, Inc. (NASDAQ: RENB). The companies have made headlines by finalizing a definitive merger agreement that...

Continue Reading
Analysts Adjust Expectations for Adobe Ahead of Earnings Report

Updated Category News Views 181

Analysts Adjust Expectations for Adobe Ahead of Earnings Report Adobe Inc. (NASDAQ: ADBE) is poised to announce its quarterly earnings figures, and the atmosphere is charged with anticipation. Analysts are forecasting a significant increase in Adobe's earnings to $5.39 per share, compared to $4.81 per share from the same period last year. This reflects an optimistic...

Continue Reading